MRK
NEUTRAL
$121.25
Live
Merck & Co., Inc. · NYSE
Target $128.26
(+5.8%)
$73.31
52W Range
$125.14
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$299.79B
P/E
16.66
ROE
36.9%
Profit margin
28.1%
Debt/Equity
0.96
Dividend yield
2.83%
AI Analysis
AI-powered fundamental assessment
Confidence
90%
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Key Strengths
Strong profitability (28.1% margin)
Strong ROE of 36.9%
Key Risks
Premium vs Graham Number ($59.01)
Weak financial trend (Piotroski F-Score: 3/9)
AI Fair Value Estimate
Based on comprehensive analysis
$50.96
-58.0% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
50
Moderate
50
50
70
30
50
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Key drivers: Strong profitability (28.1% margin), Strong ROE of 36.9%, Premium vs Graham Number ($59.01)
Confidence
50%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Trades above Graham Number.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
70/100
Historical performance + price trend: Shares moved +93.0% over 5Y and +44.3% over 1Y.
Positives
- ROE sits at 36.9%.
- Healthy profit margin of 28.1%.
Watchpoints
No urgent risks highlighted.
Health
30/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
50/100
Dividend policy fallback.
Positives
- Moderate dividend profile (Score: 50/100).
- Yield: 2.8%.
Watchpoints
No urgent risks highlighted.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$121.25
Analyst Target
$128.26
Upside/Downside
+5.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MRK and closest competitors.
Updated 2026-04-01
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MRK
Merck & Co., Inc.
Primary
|
+93.0% | +22.1% | +44.3% | +36.7% | +0.6% | +1.6% |
|
UNH
UnitedHealth Group Incorporated
Peer
|
-11.6% | -29.1% | -21.8% | -10.0% | +17.4% | +3.4% |
|
AZN
AstraZeneca PLC
Peer
|
+92.9% | +49.4% | +38.4% | +28.8% | +0.5% | -1.5% |
|
ABBV
AbbVie Inc.
Peer
|
+140.3% | +65.5% | +32.8% | +17.0% | -3.9% | +2.3% |
|
TMO
Thermo Fisher Scientific Inc.
Peer
|
+6.7% | -9.7% | +18.7% | -9.2% | +7.5% | -3.3% |
MRK
Merck & Co., Inc.
Primary
5Y
+93.0%
3Y
+22.1%
1Y
+44.3%
6M
+36.7%
1M
+0.6%
1W
+1.6%
UNH
UnitedHealth Group Incorporated
Peer
5Y
-11.6%
3Y
-29.1%
1Y
-21.8%
6M
-10.0%
1M
+17.4%
1W
+3.4%
AZN
AstraZeneca PLC
Peer
5Y
+92.9%
3Y
+49.4%
1Y
+38.4%
6M
+28.8%
1M
+0.5%
1W
-1.5%
ABB
AbbVie Inc.
Peer
5Y
+140.3%
3Y
+65.5%
1Y
+32.8%
6M
+17.0%
1M
-3.9%
1W
+2.3%
TMO
Thermo Fisher Scientific Inc.
Peer
5Y
+6.7%
3Y
-9.7%
1Y
+18.7%
6M
-9.2%
1M
+7.5%
1W
-3.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
16.66
Forward P/E
12.42
PEG Ratio
N/A
P/B Ratio
5.7
P/S Ratio
4.61
EV/Revenue
5.13
EV/EBITDA
11.46
Market Cap
$299.79B
Profitability
Profit margins and return metrics
Profit Margin
28.08%
Operating Margin
32.77%
Gross Margin
77.21%
ROE
36.88%
ROA
12.04%
Growth
Revenue and earnings growth rates
Revenue Growth
+5.0%
Earnings Growth
-19.3%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-20.8%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.96
Moderate
Current Ratio
1.54
Good
Quick Ratio
0.96
Poor
Cash/Share
$5.89
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$16.4B
Gross Margin
66.2%
Op. Margin
24.8%
Net Margin
18.1%
Total Assets
$136.9B
Liabilities
$84.2B
Equity
$52.6B
Debt/Equity
1.60x
Operating CF
$2.9B
CapEx
$-1.0B
Free Cash Flow
$1.8B
FCF Yield
64%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-03
$1.19
-29.2% surprise
2025-10-30
$2.58
+9.8% surprise
2025-07-29
$2.13
+5.0% surprise
Healthcare Sector Comparison
Comparing MRK against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
16.66
This Stock
vs
75.44
Sector Avg
-77.9%
(Discount)
Return on Equity (ROE)
36.88%
This Stock
vs
-88.14%
Sector Avg
-141.8%
(Below Avg)
Profit Margin
28.08%
This Stock
vs
-16.28%
Sector Avg
-272.5%
(Weaker)
Debt to Equity
0.96
This Stock
vs
2.66
Sector Avg
-64.0%
(Less Debt)
Revenue Growth
5.0%
This Stock
vs
124.04%
Sector Avg
-96.0%
(Slower)
Current Ratio
1.54
This Stock
vs
4.47
Sector Avg
-65.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MRK
Merck & Co., Inc.
|
NEUTRAL | $299.79B | 16.66 | 36.9% | 28.1% | $121.25 | |
|
UNH
UnitedHealth Group Incorporated
|
NEUTRAL | $293.61B | 24.43 | 12.5% | 2.7% | $323.48 | Compare |
|
AZN
AstraZeneca PLC
|
NEUTRAL | $288.2B | 30.48 | 21.7% | 16.2% | $92.95 | Compare |
|
ABBV
AbbVie Inc.
|
NEUTRAL | $387.52B | 163.63 | 138.0% | 4.0% | $219.26 | Compare |
|
TMO
Thermo Fisher Scientific Inc.
|
NEUTRAL | $191.01B | 28.99 | 13.0% | 15.0% | $513.98 | Compare |
MRK
Merck & Co., Inc.
NEUTRAL
Mkt Cap
$299.8B
P/E
16.7
ROE
36.9%
Price
$121.25
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-12 | GUINDO CHIRFI | Officer | Sale | 10,000 | $1,214,562 |
| 2026-02-10 | LI DEAN Y | Officer | Sale | 10,235 | $1,202,844 |
| 2026-02-09 | ZACHARY JENNIFER L | General Counsel | Sale | 121,573 | $14,485,690 |
| 2026-02-09 | GUINDO CHIRFI | Officer | Sale | 10,000 | $1,184,101 |
| 2026-02-09 | ZACHARY JENNIFER L | General Counsel | Option Exercise | 121,573 | $14,485,690 |
| 2026-02-06 | DELUCA RICHARD ROBERT JR. | Officer | Sale | 37,685 | $4,557,025 |
| 2026-02-06 | WILLIAMS DAVID MICHAEL | Chief Technology Officer | Sale | 5,000 | $609,525 |
| 2026-02-06 | OOSTHUIZEN JOHANNES JACOBUS | Officer | Sale | 15,000 | $1,827,992 |
| 2026-02-06 | WILLIAMS DAVID MICHAEL | Chief Technology Officer | Option Exercise | 5,000 | $388,100 |
| 2026-02-05 | GUINDO CHIRFI | Officer | Sale | 20,000 | $2,437,676 |
| 2026-02-04 | LI DEAN Y | Officer | Sale | 15,087 | $1,791,824 |
| 2026-02-04 | LITCHFIELD CAROLINE | Chief Financial Officer | Sale | 41,997 | $5,023,312 |
| 2026-02-04 | SMART DALTON E. III | Officer | Sale | 6,400 | $765,920 |
| 2026-02-04 | DAVIS ROBERT M | Chief Executive Officer | Sale | 47,434 | $5,599,327 |
| 2026-02-04 | SMART DALTON E. III | Officer | Option Exercise | 4,000 | $248,280 |
GUINDO CHIRFI
Officer
2026-02-12
10,000 shares
·
$1,214,562
LI DEAN Y
Officer
2026-02-10
10,235 shares
·
$1,202,844
ZACHARY JENNIFER L
General Counsel
2026-02-09
121,573 shares
·
$14,485,690
GUINDO CHIRFI
Officer
2026-02-09
10,000 shares
·
$1,184,101
ZACHARY JENNIFER L
General Counsel
2026-02-09
121,573 shares
·
$14,485,690
DELUCA RICHARD ROBERT JR.
Officer
2026-02-06
37,685 shares
·
$4,557,025
WILLIAMS DAVID MICHAEL
Chief Technology Officer
2026-02-06
5,000 shares
·
$609,525
OOSTHUIZEN JOHANNES JACOBUS
Officer
2026-02-06
15,000 shares
·
$1,827,992
WILLIAMS DAVID MICHAEL
Chief Technology Officer
2026-02-06
5,000 shares
·
$388,100
GUINDO CHIRFI
Officer
2026-02-05
20,000 shares
·
$2,437,676
LI DEAN Y
Officer
2026-02-04
15,087 shares
·
$1,791,824
LITCHFIELD CAROLINE
Chief Financial Officer
2026-02-04
41,997 shares
·
$5,023,312
SMART DALTON E. III
Officer
2026-02-04
6,400 shares
·
$765,920
DAVIS ROBERT M
Chief Executive Officer
2026-02-04
47,434 shares
·
$5,599,327
SMART DALTON E. III
Officer
2026-02-04
4,000 shares
·
$248,280
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
27 analysts
RBC Capital
2026-03-30
Outperform
Outperform
Citigroup
2026-03-20
Neutral
Neutral
Wells Fargo
2026-03-12
Overweight
Overweight
RBC Capital
2026-02-25
Outperform
Barclays
2026-02-20
Overweight
Freedom Broker
2026-02-09
Hold
Hold
Guggenheim
2026-02-06
Buy
Buy
Citigroup
2026-02-04
Neutral
Neutral
Cantor Fitzgerald
2026-02-04
Neutral
Neutral
Wells Fargo
2026-02-04
Overweight
Overweight
Past News Coverage
Recent headlines mentioning MRK from our newsroom.
Newest → oldest
No matching news yet.